MedTrace Logo

Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic Arthritis

NCT02475304 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-10-05

No results posted yet for this study

Summary

The purpose of this study is to investigate, whether FP187 is effective in the treatment of mild to moderate psoriatic arthritis.

Conditions

Interventions

DRUG

FP187

FP 187 is given as oral tablets twice daily, 500 mg daily

DRUG

Placebo

Sponsors & Collaborators

  • Skane University Hospital

    lead OTHER

Principal Investigators

  • Elke Theander, MD. PhD · Skåne University Hospital, Lund University, 20502 Malmö, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2016-10-31
Completion
2017-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02475304 on ClinicalTrials.gov